Aphase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Blood

Volumn 118, Issue 3, 2011, Pages 523-528

  Sekeres, Mikkael A ^a   Gundacker, Holly ^b   Lancet, Jeffrey ^c   Advani, Anjali ^a   Petersdorf, Stephen ^d   Liesveld, Jane ^e   Mulford, Deborah ^e   Norwood, Tom ^f   Willman, Cheryl L ^g   Appelbaum, Frederick R ^h   List, Alan F ^c  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Southwest Oncology Group Statistical Office   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME 5Q; CLINICAL ARTICLE; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL INFECTION; GENE DELETION; GENETIC ANALYSIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; HYPOKALEMIA; HYPONATREMIA; KIDNEY FAILURE; LUNG DISEASE; LUNG INFECTION; MALE; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN DISEASE; SKIN INFECTION; UNSPECIFIED SIDE EFFECT; VOMITING; CHROMOSOME 5; CHROMOSOME DELETION; CLINICAL TRIAL; GENETICS; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 79960687125     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-337303     Document Type: Article

References (32)

1. Surveillance Epidemiology and End Results. SEER Cancer Statistics Review, 1975-2007. http://seer.cancer.gov/csr/1975-2007/. Accessed May 19, 2011.
2. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia 10.1182/blood-2005-09-3724. Blood. 2006;107(9):3481-3485.
3. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302-1311.
4. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332(25):1671-1677.
5. Stone RM, O'Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004:98-117.
6. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479-485. (Pubitemid 38140076)
7. Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002;100(4):1224-1232. (Pubitemid 34864276)
8. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108(1):63-73. (Pubitemid 43996625)
9. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312-1320.
10. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89(9):3323-3329.
11. Lang K, Earle CC, Foster T, Dixon D, Van Gool R, Menzin J. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging. 2005;22(11):943-955. (Pubitemid 41746575)
12. Baz R, Rodriguez C, Fu AZ, et al. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. Cancer. 2007;110(8):1752-1759. (Pubitemid 47557300)
13. Löwenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7(9):1268-1274. (Pubitemid 19220128)
14. Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990;8(2):272-279. (Pubitemid 20056558)
15. Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and highrisk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009;115(24):5746-5751.
16. Burnett AKMD, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114-1124. (Pubitemid 46435390)
17. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-569.
18. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009;106(31):12974-12979.
19. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-339.
20. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465. (Pubitemid 44511560)
21. Adès L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2-or high risk myelodysplastic syndromes (MDS) with 5q deletion: Results of a phase II study. Blood. 2009;113(17):3947-3952.
22. Mesa RA, Tefferi A, Li CY, Steensma DP. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia. 2006;20(11):2063-2064. (Pubitemid 44614907)
23. Lancet JE, List AF, Moscinski LC. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia. 2007;21(3):586-588.
24. Ford CD, Asch J, Konopa K, Petersen FB. CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010;45(2):403-404.
25. Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. 2010;28(33):4919-4925.
26. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
27. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
28. Sekeres MA, O'Keefe C, List AF, et al. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol. 2011;86(1):102-103.
29. Sugimoto Y, Sekeres MA, Makishima H, et al. Cytogenetic predictors of response to lenalidomide in myeloid malignancies without Del(5q) [abstract]. Blood. 2010;116(21):4016.
30. Fehniger TA, Uy GL, Trinkaus K, et al. A phase II study of high dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. Blood. 2011;117(6):1828-1833.
31. Ades L, Prebet T, Stamatoullas A, et al. Lenalidomide (LEN) combined to intensive chemotherapy (IC) In AML and higher risk MDS with Del 5q. Results of a phase I/II study of the Groupe Francophone Des Myelodysplasies (GFM) [abstract]. Blood. 2010;116(21):508.
32. Platzbecker U, Haase D, Braulke F, et al. A phase I study of a combination of 5-azacyitidine followed by lenalidomide in high-risk MDS or AML patients with chromosome 5 "AZALE" trial [abstract]. Blood. 2010;116(21):4000.